ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Geron Corp

Geron Corp (GERN)

1.27
0.03
(2.42%)
Closed 21 April 6:00AM
1.28
0.01
(0.79%)
After Hours: 9:54AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.28
Bid
1.25
Offer
1.27
Volume
8,287,784
1.20 Day's Range 1.28
1.17 52 Week Range 5.34
Market Cap
Previous Close
1.24
Open
1.23
Last Trade Time
Financial Volume
US$ 10,220,968
VWAP
1.2333
Average Volume (3m)
15,788,728
Shares Outstanding
636,904,470
Dividend Yield
-
PE Ratio
-4.67
Earnings Per Share (EPS)
-0.27
Revenue
76.99M
Net Profit
-174.57M

About Geron Corp

Geron is a commercial-stage biopharmaceutical company focused on research, development, and commercialization of the Company's internally developed first-in-class telomerase inhibitor for the treatment of hematologic malignancies. RYTELO(R) (imetelstat) is approved in the United States and Europe fo... Geron is a commercial-stage biopharmaceutical company focused on research, development, and commercialization of the Company's internally developed first-in-class telomerase inhibitor for the treatment of hematologic malignancies. RYTELO(R) (imetelstat) is approved in the United States and Europe for treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with a telomerase inhibitor approved by the FDA and the EC, Geron is exploring the broad potential of imetelstat across multiple myeloid hematologic malignancies. In addition to its Phase 3 trial for JAK inhibitor relapsed/refractory myelofibrosis (R/R MF), Geron has programs assessing imetelstat in additional indications, as a single agent and in combination with current standard of care therapies through early-stage clinical trials.The company earns revenue through RYTELO sales and possesses global rights to imetelstat. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Geron Corp is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GERN. The last closing price for Geron was US$1.24. Over the last year, Geron shares have traded in a share price range of US$ 1.17 to US$ 5.34.

Geron currently has 636,904,470 shares in issue. The market capitalisation of Geron is US$789.76 million. Geron has a price to earnings ratio (PE ratio) of -4.67.

GERN Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.06-4.47761194031.341.391.17120372231.29578836CS
4-0.42-24.70588235291.71.891.17152169841.52160463CS
12-1.74-57.61589403973.023.121.17157887281.9525292CS
26-2.88-69.23076923084.164.51.17128204282.69744773CS
52-2.35-64.7382920113.635.341.17114097223.44437682CS
156-0.27-17.41935483871.555.341.1778849242.96286668CS
2600.086.666666666671.25.340.989960905352.66956658CS

GERN - Frequently Asked Questions (FAQ)

What is the current Geron share price?
The current share price of Geron is US$ 1.28
How many Geron shares are in issue?
Geron has 636,904,470 shares in issue
What is the market cap of Geron?
The market capitalisation of Geron is USD 789.76M
What is the 1 year trading range for Geron share price?
Geron has traded in the range of US$ 1.17 to US$ 5.34 during the past year
What is the PE ratio of Geron?
The price to earnings ratio of Geron is -4.67
What is the cash to sales ratio of Geron?
The cash to sales ratio of Geron is 10.59
What is the reporting currency for Geron?
Geron reports financial results in USD
What is the latest annual turnover for Geron?
The latest annual turnover of Geron is USD 76.99M
What is the latest annual profit for Geron?
The latest annual profit of Geron is USD -174.57M
What is the registered address of Geron?
The registered address for Geron is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Geron website address?
The website address for Geron is www.geron.com
Which industry sector does Geron operate in?
Geron operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MSGMMotorsport Games Inc
US$ 2.69
(140.18%)
37M
SXTCChina SXT Pharmaceuticals Inc
US$ 2.11
(113.37%)
51.73M
ADGMAdagio Medical Holdings Inc
US$ 1.68
(81.98%)
115.48M
PNBKPatriot National Bancorp Inc
US$ 3.28
(73.54%)
1.57M
RTCBaijiayun Group Ltd
US$ 0.3601
(67.49%)
187.02M
LXEHLixiang Education Holding Company Ltd
US$ 8.25
(-64.11%)
1.55M
CLIKClick Holdings Ltd
US$ 0.355
(-48.18%)
13.52M
IOTRiOThree Ltd
US$ 1.1409
(-38.33%)
3.93M
FMTOFemto Technologies Inc
US$ 0.0191
(-35.47%)
198.4M
SISIShineco Inc
US$ 0.5809
(-35.07%)
824.91k
DMNDamon Inc
US$ 0.0034
(9.68%)
409.39M
STSSSharps Technology Inc
US$ 0.03195
(20.57%)
391.8M
SUNESUNation Energy Inc
US$ 0.0176
(-10.20%)
349.4M
NVDANVIDIA Corporation
US$ 101.49
(-2.87%)
292.48M
HTZHertz Global Holdings Inc
US$ 8.205
(43.70%)
266.91M

GERN Discussion

View Posts
Monksdream Monksdream 21 hours ago
GERN, under $2
👍️0
Spike5 Spike5 5 days ago
See what i mean this will never see 2 again let alone 6 . Effing crazy
👍️0
big bambino big bambino 5 days ago
Geron Price Target Maintained With a $5.00/Share by Needham
March 12, 2025
07:34 AM ET
👍️ 1
Spike5 Spike5 5 days ago
Anyone saying anything good about this company is crazy
🙄 1
KIPK KIPK 1 week ago
Because "Whole", has become a Definer/Reminder of you......

You go... the flag barer of the "Whole" Team...

The Law of Resonance:::::
👍️0
learningcurve2020 learningcurve2020 1 week ago
The second somebody talks about wholes you always seem to pop up?
👍️0
KIPK KIPK 1 week ago
LOLC2020 ,,
Your statement below truly defines you - Thanks for the clarification...
>>> which is a massive difference if you’re ever trying to get whole again>>>>

Q - Have you past the Point of no return???
👍️0
Trend-Setter Trend-Setter 1 week ago
Great time to seek "Defensive Stocks" due to economic headwinds caused by tariffs.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176042856

ELTP, an otc gem on the verge of M&A...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175821245
👍️0
learningcurve2020 learningcurve2020 1 week ago
I do. But in this case we have a company with solid institutional holdings and all top management slowly accumulating options through a plan. It doesn’t seem like a candidate for self sabotage. But I do call them “Grrrrron” for a reason. Lots of suffering with this one over all the years.
👍️0
Spike5 Spike5 1 week ago
I hear what you are saying but i think that you also understand what i am saying ?!
👍️0
learningcurve2020 learningcurve2020 1 week ago
Biotech sector is in a slump for the moment so... @7 multiple X 2024 revs ($75M but for only 1/2 year in U.S. only) so about a $1billion market cap current. So maybe $500M in global revs for 2025 / 26 or $3.5B market cap ($5 share price). 🙏. We need word of treating another indication then it’s off to the races! Any buyout would add a few years rev outlook, of course. I have to believe Rytelo is a prime candidate given its unique MOA and manageable side effects? I hope we hear soon on a new CEO unless Interim CEO Bir hits the ground running.
👍️0
Spike5 Spike5 1 week ago
Well it is very clear to me that the people running this company have zero concern for shareholders. This stock has crumbled 75 % since FDA approval. That just cannot happen. It seems to me like they are trying to ruin this company. Im not saying this stock should be up to a 100 but it should be at least 10 . Its unexceptable that it will most likely under 1 dollar soon .
😂 1
learningcurve2020 learningcurve2020 1 week ago
Why rs with only 640M shares outstanding and with 80% institutional holdings? They’ve already said they’re not going to raise cash. It took a while but they’re now FDA approved and generating revenue. With the recent sp hit it seems like a good bet. Just can’t have f ups at bedside.
👍️0
Spike5 Spike5 1 week ago
This will do a reverse split by year end and then file for bankruptcy next year or completely go under . Great company 30 years to get a drug approved and this is what they do to long investors.
👍️0
KIPK KIPK 2 weeks ago
LOLC2020 - Your Reward For Your Activities for over 10 years will catch up to you....
What would you call yourself then...? KARMA
___________________
learningcurve2020

Re: Investor082 post# 759936

Wednesday, April 09, 2025 11:52:33 AM

Post#
759938
of 759938
You’ll notice all the pro pumpers have gradually disappeared
👍️0
Spike5 Spike5 2 weeks ago
Wow!! Its been a long while since i looked at this . Where is that dumbass loudmouth stumblebum?
👍️0
big bambino big bambino 2 weeks ago
picked up another 1400@1.29
👍️0
Monksdream Monksdream 2 weeks ago
GERN, new 52 week low
👍️0
seward seward 2 weeks ago
Added 5000 for a flip
👍️0
KIPK KIPK 4 weeks ago
LOLC-2020... GERN? Really??? Na.. DUDE......

Let your boss, it is AF (the GERN flipflopper) to know....game over!!
👍️0
learningcurve2020 learningcurve2020 1 month ago
Grrrron. But I’m hanging in there with them. Seems like a prime candidate now for a takeover. Now we see why they dropped the price. Terrible considering the analyst calls.

>> (Nasdaq: GERN) has announced the granting of equity awards to three newly hired employees as inducement for their employment. The awards, granted on March 17, 2025, consist of:

150,000 shares in stock options with an exercise price of $1.74 per share
75,000 shares in restricted stock units (RSUs)
The stock options have a 10-year term with a vesting schedule of 12.5% after six months and the remaining shares vesting over 42 months. RSUs vest 25% annually over four years. These awards were granted under Geron's 2018 Inducement Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Lawsuit:
>>According to the complaint, during the class period, defendants failed to disclose to investors that
Geron’s optimistic reports of Rytelo’s launch success and potential growth fell short of reality; the impacts of seasonality, existing competition, and the burden of continued monitoring played a much more significant role in patient starts than defendants had implied. Moreover, Rytelo lacked the necessary awareness to penetrate the market, resulting in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting.

The complaint alleges that on February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal 2024, disclosing that Rytelo’s growth had flattened over the preceding months. The Company attributed the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. On this news, the price of Geron’s common stock declined from a closing price of $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, a decline of about 32.07% in the span of just a single day.
👍️0
big bambino big bambino 1 month ago
Nice another law suit. I received a check for $7,023.42 on the first law suit, lol. maybe I'll pick up another check 😀
👍️0
KIPK KIPK 1 month ago
LOLC2020 - Karmic Karma!!
👍️0
learningcurve2020 learningcurve2020 1 month ago
Get back in your box, Gimp.
👍️0
KIPK KIPK 1 month ago
LOLC2020? Marketer for global sales??
Put an add on X.. LOL. LOLC
👍️0
learningcurve2020 learningcurve2020 1 month ago
Possible. But Scarlett was always better at drug development. Plus he’s getting up there. What Geron needs now is a great marketer for global sales.
👍️0
attilathehunt attilathehunt 1 month ago
Perhaps CEO needs to get out of the way for a BO to happen.
👍️0
Stumblebum Stumblebum 1 month ago
And European approval just was announced also
👍️ 1
attilathehunt attilathehunt 1 month ago
CEO stepping down...

Good news????
👍️0
KIPK KIPK 2 months ago
LOLC-2020...

SMH
👍️0
learningcurve2020 learningcurve2020 2 months ago
Oh wow, nice! I hadn’t noticed. Always encouraging. Hopefully more to come.
👍️0
luckygm luckygm 2 months ago
The insiders were bullish buying shares on the open market last Thursday.
👍️0
KIPK KIPK 2 months ago
Its the "Too Little Tooo Late" story for GERN..
LOLC??? SMH
KARMA
👍️0
learningcurve2020 learningcurve2020 2 months ago
Shouldn’t be down here but it is. Analyst are all over the place. Institutional holdings look good so far unless they’re dumping. We need a more dynamic management, IMO.

“B. Riley downgrades to Neutral from Buy, Cuts target to $2 from $3.50”
👙 1
big bambino big bambino 2 months ago
looking for 2.25 by next week
👍️0
seward seward 2 months ago
Sold the15K at 1.75
👍️0
learningcurve2020 learningcurve2020 2 months ago
That’s all I need too. You know their governance over on the other board is atrocious, right? Rarely leads to anything good. At least Geron’s management bench runs deep. I wish they’d be more active with open market purchases but if the company is really in takeover mode that wouldn’t be possible, of course. Three presentations coming in the next weeks. We’ll see.
👍️0
attilathehunt attilathehunt 2 months ago
Here we agree. On the other board not so much.

By the way, I only have one account on ihub.
👍️0
learningcurve2020 learningcurve2020 2 months ago
It would be one explanation for the action today and faux stock downgrades.

“Wedbush Lowers Geron’s Price Target to $7 from $8, Outperform Raiting Maintained”
👍️0
attilathehunt attilathehunt 2 months ago
The takedown before the buyout!!

The same happen with HGSI
👍 1 💯 1
KIPK KIPK 2 months ago
LOLC2020 - You pumped it, Its failing & you now saying "THE COMPANY IS SOLID", BUT the "ANALYSTS SEEM INTENT ON SETTING THE STOCK FOR FAILURE??

Who pays you for such misjudged PUMP Efforts here & FUD Efforts there???
👍️0
learningcurve2020 learningcurve2020 2 months ago
This would be a very good time for some open market purchases by management.
👍️0
learningcurve2020 learningcurve2020 2 months ago
The company seems solid but the analyst seem intent on setting up the stock for failure.
👍️0
learningcurve2020 learningcurve2020 2 months ago
And you think someone would believe that why?
👍️0
big bambino big bambino 2 months ago
Great purchase. picked up another 5k @ 1.92
👍️0
learningcurve2020 learningcurve2020 2 months ago
All seems good but the stock is always a death trap.

>>Selling, general and administrative expenses for the three and twelve months ended December 31, 2024, were $43.4 million, and $145.7 million, respectively, and $21.4 million and $69.1 million for the same periods in 2023. The increase in general and administrative expenses in 2024 as compared to 2023 primarily reflects higher personnel-related expenses related to increased headcount to support commercial launch of RYTELO in the U.S. and stock-based compensation expense recognized upon FDA approval of RYTELO due to the vesting of performance-based stock options.
👍️0
seward seward 2 months ago
picked up another 10000 at 1.60

👍️0
learningcurve2020 learningcurve2020 2 months ago
Grrron stock is just a disgrace…A perpetual retail trap.
💯 1
big bambino big bambino 2 months ago
picked up another 4500@ $2.40
👍️0
big bambino big bambino 2 months ago
pushing this thing down low with no news and no volume, amazing. Will wait till Wednesday before making decision.
👍️0